Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Silviu Itescu
|
| gptkbp:country |
gptkb:Australia
|
| gptkbp:focus |
regenerative medicine
stem cell therapies |
| gptkbp:founded |
2004
|
| gptkbp:founder |
Silviu Itescu
|
| gptkbp:headquarters_location |
gptkb:Melbourne
|
| https://www.w3.org/2000/01/rdf-schema#label |
Mesoblast Limited
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:market |
global
|
| gptkbp:notable_clinical_trial |
gptkb:acute_graft_versus_host_disease
chronic low back pain chronic heart failure COVID-19 ARDS |
| gptkbp:numberOfEmployees |
~70 (2023)
|
| gptkbp:product |
MPC-06-ID
MPC-150-IM remestemcel-L |
| gptkbp:stockExchange |
gptkb:ASX
|
| gptkbp:stockSymbol |
gptkb:MSB
MESO |
| gptkbp:subsidiary |
Mesoblast, Inc.
|
| gptkbp:website |
https://www.mesoblast.com/
|
| gptkbp:bfsParent |
gptkb:Joseph_R._Swedish
|
| gptkbp:bfsLayer |
7
|